Cadila Healthcare to launch tablets for insomnia
Zydus Cadila is set to launch Ramelteon Tablets (US RLD -Rozerem Tablets), 8 mg on receiving the final approval from USFDA. The shares were trading in red in the morning session.
The US Food & Drug Administration (USFDA) has given the approval for Ramelteon which is a sedative, also called a hypnotic. It works by affecting certain substances in the body that help regulate the ‘sleep-wake cycle’. Thus, Ramelteon is used to treat insomnia. The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. The group now has 270 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
The shares of the company on Wednesday opened at Rs. 235 against Tuesday’s close of Rs. 235.70. At 11:08 hours, it was trading at Rs. 234.30, 0.59 per cent lower than its previous close. The intraday high was Rs. 236.60 and intraday low was Rs. 231.55. Its 52-week high was Rs. 432.40 and 52-week low was Rs. 223.20 per share on the BSE.